{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:39:30Z","timestamp":1773927570998,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clml.2020.08.009","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T22:31:47Z","timestamp":1597703507000},"page":"836-842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4957-9856","authenticated-orcid":false,"given":"Hayri","family":"Bostan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayfur","family":"Toptas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda Pepedil","family":"Tanrikulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevser","family":"Kut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Arikan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fergun","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isik","family":"Atagunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulin","family":"Firatli-Tuglular","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.08.009_bib1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.08.009_bib2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.08.009_bib3","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.009_bib4","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic-phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study","volume":"21","author":"Hahn","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.009_bib5","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.009_bib6","first-page":"1097","article-title":"Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison","volume":"21","author":"Phillips","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2020.08.009_bib7","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.31323","article-title":"Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib","volume":"124","author":"Efficace","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.08.009_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.clml.2017.01.001","article-title":"Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second-line therapy: a multicenter prospective observational study","volume":"17","author":"Sacha","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15 Suppl","key":"10.1016\/j.clml.2020.08.009_bib9","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1200\/jco.2012.30.15_suppl.6605","article-title":"Analysis of imatinib (IM)-related, low-grade (LG), non-hematologic (heme) adverse events (AEs) in patients (pts) with chronic myeloid leukemia (CML) switched to nilotinib (NIL): ENRICH study update","volume":"30","author":"Mauro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.009_bib10","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.009_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2020.08.009_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.leukres.2012.10.021","article-title":"Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review","volume":"37","author":"Efficace","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.08.009_bib13","first-page":"135","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30","volume":"13","author":"Guzelant","year":"2004","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.clml.2020.08.009_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","article-title":"International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24","volume":"23","author":"Efficace","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2020.08.009_bib15","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.clml.2020.08.009_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.009_bib18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clml.2017.07.255","article-title":"Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and Glivec","volume":"17","author":"Eskazan","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.08.009_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4274\/tjh.2016.0409","article-title":"Assessment of quality of life of chronic myeloid leukemia patients by using the EORTC QLQ-C30","volume":"34","author":"U\u011fur","year":"2017","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.clml.2020.08.009_bib20","article-title":"The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients","volume":"26","author":"Uyanik","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clml.2020.08.009_bib21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.08.009_bib22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) trial (DASISION, CA180-056)","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.009_bib23","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.08.009_bib24","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1002\/cam4.1808","article-title":"A\u00a0prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second-and third-generation tyrosine kinase inhibitors","volume":"7","author":"Zulbaran-Rojas","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2020.08.009_bib25","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020304249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020304249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:59Z","timestamp":1761870899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020304249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2152265020304249"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}